Open AccessCase report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma
Author(s) -
Eugenio Monti,
Chiara Trambaiolo Antonelli,
Marco Mora,
Bruno Spina,
Gianluca Ansaldo,
Marsida Teliti,
Martina Comina,
Lucia Conte,
Michele Minuto,
Elisabetta Varaldo,
Simona Zupo,
Barbara Massa,
Silvia Morbelli,
Massimo Giusti
Publication year - 2019
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2019-0099
Subject(s) - medicine , lenvatinib , thyroid cancer , thyroid carcinoma , thyroidectomy , radiation therapy , biopsy , radiology , neoadjuvant therapy , oncology , thyroid , surgery , cancer , breast cancer
We report a case of an elderly woman presenting with a huge cervical mass invading the tracheal lumen. Diagnosed as invasive poorly differentiated thyroid cancer, after an endotracheal biopsy, stenting and radiotherapy, it was judged eligible for total thyroidectomy, but surgery was delayed due to pulmonary thromboembolism. The patient was therefore treated with lenvatinib with a neoadjuvant intent until hemodynamic stability was obtained. Thyroidectomy and radioiodine therapy were then performed and the postdose scan revealed an area of modest uptake in the anterior part of the neck. The patient is now in a good clinical status and she continues her follow-up program without any adjuvant therapy.